Coherus BioSciences Inc (CHRS)
0.7284
+0.06
(+8.72%)
USD |
NASDAQ |
Nov 05, 16:00
Coherus BioSciences Net Income (Quarterly): -12.92M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -12.92M |
| March 31, 2024 | 102.88M |
| December 31, 2023 | -79.65M |
| September 30, 2023 | -39.64M |
| June 30, 2023 | -42.87M |
| March 31, 2023 | -75.73M |
| December 31, 2022 | -58.87M |
| September 30, 2022 | -86.65M |
| June 30, 2022 | -50.15M |
| March 31, 2022 | -96.08M |
| December 31, 2021 | -45.72M |
| September 30, 2021 | -38.53M |
| June 30, 2021 | -29.90M |
| March 31, 2021 | -172.95M |
| December 31, 2020 | 9.708M |
| September 30, 2020 | 27.93M |
| June 30, 2020 | 59.03M |
| March 31, 2020 | 35.57M |
| December 31, 2019 | 39.23M |
| September 30, 2019 | 47.04M |
| June 30, 2019 | 23.57M |
| March 31, 2019 | -20.00M |
| Date | Value |
|---|---|
| December 31, 2018 | -62.60M |
| September 30, 2018 | -58.81M |
| June 30, 2018 | -43.64M |
| March 31, 2018 | -44.30M |
| December 31, 2017 | -49.07M |
| September 30, 2017 | -58.99M |
| June 30, 2017 | -55.34M |
| March 31, 2017 | -74.78M |
| December 31, 2016 | -75.92M |
| September 30, 2016 | 83.94M |
| June 30, 2016 | -69.97M |
| March 31, 2016 | -65.39M |
| December 31, 2015 | -52.39M |
| September 30, 2015 | -71.33M |
| June 30, 2015 | -58.81M |
| March 31, 2015 | -40.72M |
| December 31, 2014 | -29.13M |
| September 30, 2014 | -7.872M |
| June 30, 2014 | -24.96M |
| March 31, 2014 | -25.17M |
| December 31, 2013 | -14.59M |
| September 30, 2013 | -21.47M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-172.95M
Minimum
Mar 2021
102.88M
Maximum
Mar 2024
-29.23M
Average
-39.64M
Median
Sep 2023
Net Income (Quarterly) Benchmarks
| Repligen Corp | 3.321M |
| Evoke Pharma Inc | -1.267M |
| Personalis Inc | -12.80M |
| Maravai LifeSciences Holdings Inc | -7.585M |
| Tempus AI Inc | -552.21M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 64.98M |
| Total Expenses (Quarterly) | 85.49M |
| EPS Diluted (Quarterly) | -0.11 |
| Enterprise Value | 182.05M |
| Gross Profit Margin (Quarterly) | 56.34% |
| Profit Margin (Quarterly) | -19.88% |
| Earnings Yield | -54.91% |
| Normalized Earnings Yield | -236.65 |